This house believes that sulphonylureas should not be used routinely as second-line treatments for patients with type 2 diabetes

This house believes that sulphonylureas should not be used routinely as second-line treatments for patients with type 2 diabetes

Sulphonylureas (SU) have received a terrible press in recent years. A series of publications over many years have told us that SUs increase the risk of adverse cardiovascular outcomes in diabetes patients (usually relative to metformin in observational studies),1 analyses from ACCORD and other mega...

書誌詳細
主要な著者:	Ryder, R, Holman, R, Gwilt, M
フォーマット:	Conference item
出版事項:	Association of British Clinical Diabetologists 2016

類似資料

Sulphonylurea failure in type 2 diabetes: treatment with a basal insulin supplement.
著者:: Holman, R, 等
出版事項: (1987)

Sulphonylureas in the management of type 2 diabetes: To be or not to be?
著者:: André J. Scheen
出版事項: (2021-01-01)

Sulphonylurea therapy over six years does not delay progression to diabetes
著者:: Herlihy, O, 等
出版事項: (2000)

Efficacy over six years of sulphonylurea plus insulin therapy in type 2 diabetic patients in the UKPDS
著者:: Cull, C, 等
出版事項: (2000)

Sulphonylureas and hypoglycaemia.
著者:: Ferner, R, 等
出版事項: (1988)

UKPDS 18: Estimated dietary intake in type 2 diabetic patients randomly allocated to diet, sulphonylurea or insulin therapy
著者:: Eeley, E, 等
出版事項: (1996)

UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years
著者:: Matthews, DR, 等
出版事項: (1998)

Factors influencing utilization of different types of sulphonylureas amongst type 2 diabetes patients
著者:: Huri, H.Z., 等
出版事項: (2010)

UKPDS 18: estimated dietary intake in type 2 diabetic patients randomly allocated to diet, sulphonylurea or insulin therapy. UK Prospective Diabetes Study Group.
著者:: Eeley, E, 等
出版事項: (1996)

Permanent neonatal diabetes: combining sulphonylureas with insulin may be an effective treatment
著者:: Misra, S, 等
出版事項: (2018)

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
著者:: Turner, R, 等
出版事項: (1998)

New uses for old drugs: neonatal diabetes and sulphonylureas.
著者:: Ashcroft, F
出版事項: (2010)

Neonatal Diabetes Caused by Activating Mutations in the Sulphonylurea Receptor
著者:: Peter Proks
出版事項: (2013-06-01)

UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group.
著者:: Matthews, DR, 等
出版事項: (1998)

Post-prandial amylin concentrations are increased by sulphonylurea, but unchanged by basal insulin, in NIDDM
著者:: Rachman, J, 等
出版事項: (1996)

Extent of satisfaction with tablets and food-timing in sulphonylurea-treated diabetes.
著者:: Woodcock, A, 等
出版事項: (2007)

Should I believe all the truths?
著者:: Greenberg, A
出版事項: (2018)

Pharmacogenetics in Type 2 diabetes: variation in TCF7L2 influences response to sulphonylureas
著者:: Pearson, E, 等
出版事項: (2007)

Stem cells in cancer : should we believe or not? /
著者:: Grande, Enrique, 等
出版事項: (2014)

Sulphonylureas and the rise and fall of beta-cell function
著者:: Matthews, DR, 等
出版事項: (2005)

Identification of First Case of Neonatal Diabetes in Singapore and Successful Conversion from Insulin to Sulphonylurea
著者:: Rashida Vasanwala MD (Paeds), MRCPCH (UK), 等
出版事項: (2010-06-01)

The clinical aspects ot the sulphonylurea compounds from the position of the cardioprotective approach at patient with type 2 diabetes, using glucocardiomonitoring
著者:: N. A. Chernikova, 等
出版事項: (2022-10-01)

Clinical outcomes and health care costs combining metformin with sitagliptin or sulphonylureas or thiazolidinediones in uncontrolled type 2 diabetes patients
著者:: Degli Esposti L, 等
出版事項: (2014-10-01)

Interactions between nicorandil and sulphonylureas: a structural basis.
著者:: Reimann, F, 等
出版事項: (2001)

Should metformin remain the first-line therapy for treatment of type 2 diabetes?
著者:: Chelsea Baker, 等
出版事項: (2021-01-01)

Indirect comparison of lixisenatide versus neutral protamine Hagedorn insulin as add-on to metformin and sulphonylurea in patients with type 2 diabetes mellitus
著者:: Fournier, Marie, 等
出版事項: (2014-10-01)

Promiscuous coupling between the sulphonylurea receptor and inwardly rectifying potassium channels.
著者:: Ammälä, C, 等
出版事項: (1996)

Should All Men with Type 2 Diabetes Be Routinely Prescribed a Phosphodiesterase Type 5 Inhibitor?
著者:: Geoffrey Hackett
出版事項: (2020-07-01)

Homozygous hypomorphic HNF1A alleles are a novel cause of young-onset diabetes and result in sulphonylurea sensitive diabetes
著者:: Misra, S, 等
出版事項: (2020)

Effects of protein phosphorylation on the sulphonylurea receptor of the pancreatic beta-cell.
著者:: Niki, I, 等
出版事項: (1997)

Binding of sulphonylureas to plasma proteins – a KATP channel perspective
著者:: Proks, P, 等
出版事項: (2018)

Alternative MDR splicing is required for direct potentiation of exocytosis by sulphonylureas
著者:: Wendt, A, 等
出版事項: (2001)

Binding of sulphonylureas to plasma proteins - A KATP channel perspective.
著者:: Peter Proks, 等
出版事項: (2018-01-01)

Should an echocardiographic scan be done routinely for infants of diabetic mothers?
著者:: M Vural, 等
出版事項: (1995-10-01)

A heterozygous activating mutation in the sulphonylurea receptor SUR1 (ABCC8) causes neonatal diabetes.
著者:: Proks, P, 等
出版事項: (2006)

Differential interactions of nateglinide and repaglinide on the human beta-cell sulphonylurea receptor 1.
著者:: Hansen, A, 等
出版事項: (2002)

To believe or not to believe
著者:: Chistine Kuruç
出版事項: (1989-12-01)

Continued Dispensing: what medications do patients believe should be available?
著者:: Salem Hasn Abukres, 等
出版事項: (2015-05-01)

Lack of association between KCNJ11 (rs5219) and ABCC8 (rs757110) polymorphisms and sulphonylurea treatment response in type 2 diabetes patients in Novosibirsk region
著者:: Irina Arkad'evna Bondar, 等
出版事項: (2015-03-01)

Involvement of the n-terminus of Kir6.2 in coupling to the sulphonylurea receptor.
著者:: Reimann, F, 等
出版事項: (1999)